Deals, Partnering

Genmab reaches second milestone in Lundbeck collaboration

Posted on 13 February 2012

Tags: , ,

Genmab announced it had reached the second pre-clinical milestone in the collaboration with H. Lundbeck, triggering a €1 million payment. 

Genmab has reached the second milestone in the collaboration with H. Lundbeck A/S to create and develop human antibody therapeutics for disorders of the central nervous system (CNS).

The milestone triggers a payment of €1 million to Genmab. Under the collaboration with Lundbeck Genmab creates novel human antibodies to three targets identified by Lundbeck and Lundbeck has access to Genmab's antibody creation and development capabilities, including its state of the art, fully automated pre-clinical antibody screening and characterization capabilities and its proprietary stabilized IgG4 and UniBody therapeutic antibody platforms.

Under the terms of the agreement, Genmab received an upfront payment of €7.5 million in October 2010 (approximately DKK 56 million).

Lundbeck fully funds the development of the antibodies.

If all milestones in the agreement are achieved, the total value of the agreement to Genmab would be approximately €38 million (approximately DKK 283 million), plus single-digit royalties.

Print Friendly, PDF & Email

Leave a Reply